NeoGenomics director exercises RSUs, gets new awards
NeoGenomics director Michael Aaron Kelly reported equity compensation activity.
Rhea-AI Filing Summary
NeoGenomics director Michael Aaron Kelly reported equity compensation activity. On June 1, 2026, he exercised 23,077 restricted stock units into common stock at $0.00 per share, bringing his direct common stock holdings to 67,086 shares. A trust associated with him also holds 5,000 common shares indirectly.
He received a new grant of 15,970 restricted stock units and 11,069 stock options with a $10.52 exercise price, both scheduled to vest or become exercisable on June 1, 2027. The filing also lists several existing stock option awards with exercise prices ranging from $7.28 to $40.90 and expirations between 2027 and 2035, indicating a continuing long-term equity position.
Positive
- None.
Negative
- None.
Insider Trade Summary
23,077 shares exercised/converted
Exercise
11 txns
Insider
Kelly Michael Aaron
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 23,077 | $0.00 | $0.00 |
| Grant/Award | Stock Option (Right to Buy) | 11,069 | $0.00 | $0.00 |
| Grant/Award | Restricted Stock Unit | 15,970 | $0.00 | $0.00 |
| Exercise | Common Stock | 23,077 | $0.00 | $0.00 |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Unit — 15,970 contracts (Direct);
Stock Option (Right to Buy) — 64,020 contracts for 52,951 underlying shares (Direct);
Common Stock — 67,086 shares (Direct);
Common Stock — 5,000 shares (Indirect, M Kelly & B Kelly TTEE Michael and Bonnie Kelly Revocable Trust DTD 05/02/2016)
Footnotes (2)
- F1. Reflects release of restricted stock units that were previously reported on a Form 4.
- F2. Once vested, the shares of common stock are not subject to expiration.
Key Figures
RSUs exercised into common stock: 23,077 shares
Direct common shares after transactions: 67,086 shares
Indirect common shares in trust: 5,000 shares
+3 more
6 metrics
RSUs exercised into common stock
23,077 shares
Restricted stock units converted on June 1, 2026
Direct common shares after transactions
67,086 shares
Common stock held directly following June 1, 2026 activity
Indirect common shares in trust
5,000 shares
Held by Michael and Bonnie Kelly Revocable Trust
New RSU grant
15,970 units
Restricted stock units granted June 1, 2026, vesting June 1, 2027
New stock option grant
11,069 options at $10.52
Options granted June 1, 2026, expiring June 1, 2036
Option exercise price range
$7.28–$40.90 per share
Existing stock options with expirations 2027–2035
Key Terms
Restricted Stock Unit, Stock Option (Right to Buy), exercise price, Form 4, +1 more
5 terms
Restricted Stock Unit financial
"Reflects release of restricted stock units that were previously reported on a Form 4."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with exercise prices such as 10.5200 and expirations into 2036."
exercise price financial
"Stock option grants include an exercise price of 10.5200 per share."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Form 4 regulatory
"restricted stock units that were previously reported on a Form 4."
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
derivative exercise/conversion financial
"Transaction code M is described as derivative exercise/conversion of restricted stock units."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did NeoGenomics (NEO) director Michael Aaron Kelly report on this Form 4?
He reported equity compensation changes, including exercising 23,077 restricted stock units into common stock and receiving new grants of restricted stock units and stock options, all dated June 1, 2026, with no open-market share sales disclosed.
What new restricted stock units did Michael Aaron Kelly receive from NeoGenomics (NEO)?
He received a grant of 15,970 restricted stock units on June 1, 2026. These units are scheduled to convert into an equal number of NeoGenomics common shares when they vest on June 1, 2027, assuming applicable vesting conditions are satisfied.
What new stock options were granted to Michael Aaron Kelly by NeoGenomics (NEO)?
He was granted 11,069 stock options with a $10.52 exercise price on June 1, 2026. These options become exercisable on June 1, 2027 and are scheduled to expire on June 1, 2036, if not exercised earlier.
What other stock options does Michael Aaron Kelly hold in NeoGenomics (NEO)?
He holds several existing option awards over NeoGenomics common stock, including grants with exercise prices of $7.28, $8.10, $13.71, $14.82, $37.53, and $40.90 per share, with expiration dates from 2027 through 2035.
AI-generated analysis. How Rhea-AI works. Not financial advice.
